

**CAMBRIDGE INTERNATIONAL EXAMINATIONS****GCE Advanced Subsidiary Level and GCE Advanced Level****MARK SCHEME for the May/June 2013 series****9700 BIOLOGY****9700/22**

Paper 2 (AS Structured Questions), maximum raw mark 60

This mark scheme is published as an aid to teachers and candidates, to indicate the requirements of the examination. It shows the basis on which Examiners were instructed to award marks. It does not indicate the details of the discussions that took place at an Examiners' meeting before marking began, which would have considered the acceptability of alternative answers.

Mark schemes should be read in conjunction with the question paper and the Principal Examiner Report for Teachers.

Cambridge will not enter into discussions about these mark schemes.

Cambridge is publishing the mark schemes for the May/June 2013 series for most IGCSE, GCE Advanced Level and Advanced Subsidiary Level components and some Ordinary Level components.

<b>Page 2</b>	<b>Mark Scheme</b>	<b>Syllabus</b>	<b>Paper</b>
	<b>GCE AS/A LEVEL – May/June 2013</b>	<b>9700</b>	<b>22</b>

Mark scheme abbreviations:

<b>;</b>	separates marking points
<b>/</b>	alternative answers for the same point
<b>R</b>	reject
<b>A</b>	accept (for answers correctly cued by the question, or by extra guidance)
<b>AW</b>	alternative wording (where responses vary more than usual)
<b><u>underline</u></b>	actual word given must be used by candidate (grammatical variants excepted)
<b>max</b>	indicates the maximum number of marks that can be given
<b>ora</b>	or reverse argument
<b>mp</b>	marking point (with relevant number)
<b>ecf</b>	error carried forward
<b>I</b>	ignore

<b>Page 3</b>	<b>Mark Scheme</b>	<b>Syllabus</b>	<b>Paper</b>
	<b>GCE AS/A LEVEL – May/June 2013</b>	<b>9700</b>	<b>22</b>

1 (a) (i) *if one box of a pair left blank, no mark for that row  
mark first on row unless one row left completely blank*

	<i>mitosis</i>	<i>meiosis</i>
1	diploid / two chromosome sets / 2n	haploid / one chromosome set / n ;
2	same number of chromosomes as parent / AW	half the number of chromosomes as parent / AW ;
3	two, copies / alleles / forms, of each	one, copy / allele / form, of each ;
4	(cells) <u>genetically</u> identical (to, each A (cells have) same / AW, DNA / A no genetic variation	(cells) <u>genetically</u> different A (cells have) different / AW, DNA / genetic material A genetic variation ;

[max 2]

- (ii) 1 for sexual reproduction ; A for, gamete / sperm and egg / pollen and ovum, formation or A gametogenesis
- 2 to produce, haploid cells / cells with one set of chromosomes, for, fertilisation / fusion ; A to form zygote  
A cells with half the number of chromosomes for, fertilisation / fusion
- 3 restores / AW, diploid / original, number when, fertilisation / fusion (of gametes) occurs ; *only need ref. to fertilisation / zygote once*
- 4 *idea of* ploidy consequences at fertilisation if not ;  
e.g. ref. to doubling of chromosome number of original
- 5 ref. genetic variation, linked to evolution / natural selection; [max 2]

(b) (i) 13  $\mu\text{m}$  ; ; *two marks for correct calculation  
(39 000 / 3000)  
allow one mark  
if calculation of 12.6  $\mu\text{m}$  or 13.3  $\mu\text{m}$  (i.e. measured as 38 mm or 40 mm and not rounded to nearest micrometre)  
measurement of, 39 mm / 3.9 cm, incorrectly converted to  $\mu\text{m}$  but correct formula used (i.e. divided by 3000)* [2]

(ii) *assume cancer cell unless stated otherwise*  
(undergoing) uncontrolled, mitosis / division ; A fast / rapid / abnormally

mitochondria, provide / produce, ATP ; R ATP energy  
A provide energy R produce energy

RER, produce / synthesise / make / AW, (more), proteins / enzymes, for (cell) growth / mitosis / division ; *if mp 1 gained, no need ref. to mitosis* [max 2]

[Total: 8]

Page 4	Mark Scheme	Syllabus	Paper
	GCE AS/A LEVEL – May/June 2013	9700	22

## 2 (a)

1	transport of water and mineral ions ; <b>A</b> minerals
2	elongated cells / cells end to end (to form) tubes for transport ; <b>A</b> (e)long(ated) tubes for transport
3	no, end / cross, walls <i>or</i> end / cross, walls broken down so minimal resistance to / unimpeded / free, flow of water ; <b>AW</b>
4	hollow / no cytoplasm / no contents / no organelles / empty, <i>ignore</i> dead so more space for greater volume to flow / greater volume per unit <i>or</i> minimal resistance to / unimpeded / free, flow of water ; <b>AW</b>
5	cellulose lining <b>A</b> cellulose walls so hydrophilic / adhesion of water molecules / for movement of water up stem / to maintain column of water / <b>AW</b> ; <b>A</b> hydrophilic lining, for movement of water up stem / to maintain column of water
6	lignified (walls) / walls contain(s) lignin <b>A</b> thickened walls <b>R</b> lined with lignin so prevents (inward) collapse / withstands negative pressure <b>R</b> prevents bursting
7	lignified (walls) / walls contain(s) lignin <b>A</b> thickened walls <b>R</b> lined with lignin so waterproof / prevents loss of water / prevents leakage / maintains column
8	additional ref. to lignin ; e.g. for support of plant spiral / annular, thickening allows elongation (of stem) for support of plant
9	pits / pitted walls to allow, sideways / lateral, movement (of water) <i>or</i> to connect to all parts of plant / <b>AW</b> ;
10	relevant ref. to diameter of lumen ; e.g. narrow, for adhesion <b>R</b> capillarity (relatively) wide to transport maximum volume of water

[max 5]

<b>Page 5</b>	<b>Mark Scheme</b>	<b>Syllabus</b>	<b>Paper</b>
	<b>GCE AS/A LEVEL – May/June 2013</b>	<b>9700</b>	<b>22</b>

**(b) look for ora**

- 1 can observe living tissue ; **A** observing processes (e.g. like mitosis)
- 2 ref. portability ; e.g. ref. to size, easy to move, no requirement for special room (e.g. vibration-free )
- 3 ease of use, qualified ; e.g. no technical training required, slide preparation easier, takes less time
- 4 see (actual / natural / real-life) colour ;
- 5 ref. to, differential staining / staining particular types of tissue ;
- 6 fewer problems with artefacts ;
- 7 lower cost of, purchase / maintenance / running / AW ; [max 2]

**[Total: 7]**

**3 (a) 1** caused by, a pathogen ;

- 2 transmissible / communicable ; **A** passed from, person / animal, to person  
*ignore* contagious

*in context of tuberculosis*

- 3 (pathogen is) a bacterium / *Mycobacterium (tuberculosis / bovis)* / *M. tuberculosis* / *M. bovis* ;

- 4 mode of transmission detail ; *one from aerosol / droplet*, infection / transmission  
in droplets, from (infected) person, exhaling / AW *if both of these*  
/ coughing / sneezing / talking in droplets, / inhaled / *given this is also*  
AW, by (uninfected) person *mp 2* }  
person, drinks (unpasteurized) milk / eats meat, from infected cattle

**A** contaminated, milk / meat

[max 3]

**(b) 1** kill bacteria / bactericidal ; **A** cause bacteria to, lyse / burst **A** destroy

- 2 (or) bacteriostatic / prevents bacterial growth / prevents bacterial replication;  
**A** ref. to preventing protein synthesis / inhibiting metabolic reactions

- 3 ref. to preventing spread (of bacteria) within body ; **A** prevents reservoir for re-infection

- 4 do not affect, human cells / human tissue / not toxic (to humans) ;

- 5 prevents death / consequences may be fatal if no antibiotic treatment / AW ;  
**A** ref. to, alleviating symptoms / faster recovery  
**A** restores good health / person feels well again / person cured

- 6 ref. to role in preventing, transmission / spread, of disease ; *do not confuse with mp 3*

Page 6	Mark Scheme	Syllabus	Paper
	GCE AS/A LEVEL – May/June 2013	9700	22

- 7 ref. to (antibiotic) treatment of TB ; e.g.  
*one of* isoniazid, rifampicin (rifampin), pyrazinamide, ethambutol, streptomycin  
*one of* 6–12 months (latent), longer for active disease, two years or more for drug-resistant forms  
 need combination treatment if active disease  
 ref. to, MDR-TB / multidrug-resistant TB *or* XDR-TB / extensively drug-resistant TB
- 8 part of DOTS regimen / described ;  
 (*directly observed therapy short-course / direct observation treatment short course*)  
 [max 4]
- (c) 1 statistical, correlation / link / association, between smoking and TB ; AW  
 A another valid suggestion in addition to mps 2-6 suggesting link
- 2 where TB, cases / death rates, are high tobacco smoking is also high ;
- 3 in areas where there is, no overcrowding / AW, smokers have higher number of TB cases ;
- 4 (ref. projects) death rates from TB reduced where patients stop smoking ;
- 5 higher cases TB in work places where smoking occurs ;
- 6 higher cases of TB in children living with parents who smoke ; [max 2]
- (d) 1 lack of / paralysed / AW, cilia, so mucus, not wafted away / accumulates ;  
 R dead cilia
- 2 pathogen / bacteria / *Mycobacterium*, remains in lungs / accumulates ;
- 3 ref. to increased opportunity / AW, for bacteria to, enter cells / infect ;
- 4 nutrients provided by excess mucus encourage growth ; AW
- 5 smoking weakens the immune system ;
- 6 detail ; e.g. fewer / less active / AW, phagocytes / macrophages [max 3]
- (e) coronary bypass (surgery) / coronary artery bypass (graft) ;  
 A bypass, surgery / graft / operation  
 R heart bypass  
 heart transplant ;  
 angioplasty ;  
 stent (insertion / AW) ; [max 2]
- [Total: 14]

<b>Page 7</b>	<b>Mark Scheme</b>	<b>Syllabus</b>	<b>Paper</b>
	<b>GCE AS/A LEVEL – May/June 2013</b>	<b>9700</b>	<b>22</b>

- 4 (a) glycosidic ; **A** glucosidic [1]
- (b) **A** = trehalose ;  
**B** = maltose ;  
**C** = cellobiose ;  
**D** = sucrose ; [max 3]
- (c) 1 *idea of separation / barrier / AW, from surroundings / external environment ;*  
2 *regulates / controls / AW, entry / exit, substances / named substances ;*  
3 *enables recognition of self (antigens) / cell recognition / avoids cell destruction / act as antigens / AW ;*  
4 *allows binding of / receptors for, hormones / signal molecules / neurotransmitters / antigens ;*  
5 *cell to cell adhesion ;*  
6 *location for enzymes / multi-enzyme systems / enzyme pathways ;*  
7 *AVP ; e.g. idea of flexibility (for some cells, ref. glycoproteins / glycolipids, form H bonds with water for stability* [max 3]
- (d) (i) 1 *active site has, specific / particular, shape ;*  
2 *complementary to substrate ; **A** substrate fits into active site*  
3 *ref. to (some enzymes) induced fit mechanism ; **A** described*  
4 *formation of enzyme-substrate complex ; AW*  
5 *lowering, activation energy /  $E_a$  ; **A** detail of how activation energy lowered  
e.g substrates held close together for bond formation  
facilitates transfer of electrons  
places strain on bond(s) to be broken* [max 3]
- (ii) 1 *loss of tertiary structure / hydrogen bonds broken / ionic bonds broken ;  
**R** if include disulfide or peptide bonds*  
2 *changes shape / substrate unable to fit, active site; **A** enzyme changes shape so alters active site*  
3 *loss of / AW, globular structure ;*  
4 *hydrophobic groups to outside of molecule ;*  
5 *hydrophilic groups no longer interact with water / AW ;* [max 2]

<b>Page 8</b>	<b>Mark Scheme</b>	<b>Syllabus</b>	<b>Paper</b>
	<b>GCE AS/A LEVEL – May/June 2013</b>	<b>9700</b>	<b>22</b>

(e) *penalise once for no units*

- 1 with no cryoprotectant, enzyme (remains), inactive / AW ;  
A at 0 mmol of cryoprotectant, 0% (of maximum) activity
- 2 for both, increasing concentration increases % (enzyme) activity recovered ;  
A comparative data quote with ref. to increase *need units*
- 3 trehalose, steeper curve / AW, up to 10 mmol (cryoprotectant) ; ora **R** rapid
- 4 at all concentrations (below 90 mmol), trehalose has higher percentage of (maximum enzyme) activity
- 5 comparative data quote to support either mps 3 or 4 ;  
for mp 3 trehalose from 0 to 80% and glycerol from 0 to 10%
- 6 both cryoprotectants can produce, 100% / maximum, (enzyme, activity / recovery) ;
- 7 trehalose produces, 100% (enzyme) activity / full (enzyme) recovery at,  
lower concentrations than glycerol / 30 mmol  
compared to, 90-100 (mmol) ; *this is also mp 6*
- 8 trehalose more effective than glycerol (up to 90 – 95 mmol cryoprotectant) ;  
A trehalose is a better cryoprotectant (than glycerol)

[max 4]

**[Total: 16]**



<b>Page 9</b>	<b>Mark Scheme</b>	<b>Syllabus</b>	<b>Paper</b>
	<b>GCE AS/A LEVEL – May/June 2013</b>	<b>9700</b>	<b>22</b>

- 5 (a) *three from ;;;*  
*allow mps without naming DNA / RNA if already gained in previous point*  
*must be comparison statement per row*  
*mark first comparison per row unless one row left blank*

	<i>DNA replication</i>	<i>DNA transcription</i>
1	DNA, formed / AW	mRNA / pre-mRNA (transcript) , (formed)
2	two (identical) DNA <u>molecules</u> formed	one mRNA <u>molecule</u> (formed)
3	product double-stranded DNA	product single stranded (m)RNA
4	all of DNA molecule, replicated / unwinds / involved	part of DNA molecule / gene, involved
5	both strands involved	one strand (involved) <i>treat ref. to sense / antisense strands as neutral</i>
6	(involves / uses) DNA polymerase	RNA polymerase
7	(free) DNA nucleotides, required / used	RNA nucleotides
8	(process involves complementary) base pairing A–T <i>ignore C–G</i>	(complementary) base pairing A–U
9	takes place in late interphase / S-phase / synthesis phase	takes place throughout interphase
10	important in, cell division / mitosis / meiosis	for, polypeptide / protein, synthesis

[max 3]

- (b) change / alteration / AW, in sequence / order / arrangement, of, bases /nucleotides (of DNA / gene) ; change to give a new allele ;

one additional detail ;  
 (may result in) altered, changed / non-functioning / no, polypeptide / protein  
 ref. to changed genetic code / different codons  
 different sequence of amino acids / different primary structure  
 named type of mutation  
 example e.g. HbS

[max 2]

- (c) (i) ref. specificity ; *in context of the immune response*  
 qualified ; e.g. existing , (B / T) lymphocytes / B-cells / T-cells, no longer activated / no recognition ora  
**R** if T lymphocytes produce antibodies  
 existing plasma cells do not produce new antibody ora  
 existing memory cells no longer activated / AW ora  
 different / new, immune response required ora

[2]

<b>Page 10</b>	<b>Mark Scheme</b>	<b>Syllabus</b>	<b>Paper</b>
	<b>GCE AS/A LEVEL – May/June 2013</b>	<b>9700</b>	<b>22</b>

(ii) artificial active / active artificial / active acquired artificial / acquired active artificial ; [1]

(d) *penalise once if not worded as a problem*

- 1 ref. malnourishment / poor diet, vaccine ineffective / poor immune response / insufficient protein for antibody production ;
- 2 some (healthy) people do not respond to vaccines ;
- 3 one-dose not always effective / problems administering boosters ; AW
- 4 ref. percentage cover / herd immunity, insufficient ; **A** description  
**A** idea of people in rural areas have less / no, access to vaccine  
**A** people avoid vaccine, worry about side-effects / other reason
- 5 ref. cost to authorities ; e.g. of, administering vaccination programme
- 6 people in some areas cannot afford to buy vaccine
- 7 vaccine may not be thermostable ; AW
- 8 high density of population / overcrowding, increases chance of spread ; [max 2]

**[Total: 10]**

6 (a) *all correct ;;;*

<i>event</i>	<i>sequence</i>
Purkyne tissue conducts the wave of excitation	4
atrioventricular node sends out a wave of excitation	3
atria contract	2
ventricles contract	5
sinoatrial node sends out a wave of excitation	1

*if not correct sequence, mark to max 2*

SAN = 1 ;

atria contract before ventricles ;

[max 3]

- (b) left ventricle pumps blood to the body, right ventricle pumps blood to the lungs ;  
 (left) round the body further distance / (right) to lungs shorter distance ; AW  
 (left) greater force required / (right) less force required ; **A** (left) blood needs to be pumped at a higher pressure / (right) blood needs to be pumped at a lower pressure  
**A** needs to overcome greater resistance  
 less force / lower pressure, to lungs, to prevent damage to capillaries ;

[max 2]

**[Total: 5]**